Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

• Status: Not yet recruiting
• Trial end date: 2024-05-01

Summary

This phase II trial tests whether TRC102 (methoxyamine hydrochloride) in combination with pemetrexed, cisplatin, and radiation therapy works to shrink tumors in patients with stage III non-squamous non-small cell lung cancer. Chemotherapy drugs, such as TRC102, pemetrexed, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy sources to kill tumor cells and shrink tumors. Giving TRC102 in combination with pemetrexed, cisplatin, and radiation therapy may help stabilize the cancer and lengthen survival time in patients with non-small cell lung cancer.

• Phase: Phase 2

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Antibodies, Monoclonal; Cisplatin; Durvalumab; Immunoglobulin G; Immunoglobulins; Pemetrexed